Chronic Conditions
Chronic conditions such as heart failure, diabetes, and chronic pain require ongoing management and care. At JCRC-ABT CellGene Innovations, we provide regenerative therapies, including MSC-based treatments and immunotherapy, designed to address the underlying causes, improve patient outcomes, and reduce the long-term impact of these conditions on daily life.
What Are Chronic Conditions?
Chronic conditions are long-term health challenges that persist over time, often requiring continuous treatment and lifestyle adjustments. Conditions such as diabetes, heart disease, and chronic pain can affect various systems in the body, leading to fatigue, mobility issues, and reduced quality of life.
Traditional treatments for chronic conditions often focus on managing symptoms. However, advanced regenerative approaches aim to restore tissue function, regulate inflammation, and improve overall health by addressing the root causes of these conditions.
Benefits of Our Treatments for Chronic Conditions
Tissue Regeneration
MSC-based stem cell therapies promote the repair of damaged tissues, such as heart muscle in heart failure or nerve tissues in chronic pain conditions, helping restore function and reduce symptoms.
Inflammation Management
Immunotherapy reduces chronic inflammation, a key contributor to many chronic diseases, improving overall health and reducing disease progression.
Improved Metabolic Function
Advanced therapies like gene therapy can address genetic factors contributing to diabetes, offering a targeted approach to improving insulin regulation and metabolic health.
Enhanced Mobility and Pain Relief
Regenerative treatments alleviate chronic pain and improve joint or muscle function, enabling patients to regain independence and live more actively.
Why Choose Us?
At JCRC-ABT CellGene Innovations, we take a patient-centric approach to managing chronic conditions, combining cutting-edge therapies with personalized treatment plans. Our focus is on delivering sustainable improvements that help you regain control over your health and well-being.
1. What chronic conditions can JCRC-ABT treat?
We treat conditions such as heart failure, diabetes, chronic pain, and other long-term health challenges that affect daily living.
2. How do regenerative therapies help in chronic conditions?
Regenerative therapies address the underlying causes of chronic conditions by repairing damaged tissues, reducing inflammation, and improving overall function.
3. Are these treatments a replacement for traditional medications?
In many cases, regenerative therapies complement traditional treatments and may reduce reliance on long-term medications over time.
4. How long does it take to see results?
The timeline for improvement varies by condition and individual. Some patients report noticeable benefits within weeks, while others require several months for full effects.
5. Can chronic conditions be cured with regenerative therapies?
While not all chronic conditions can be cured, our therapies aim to significantly improve quality of life, reduce symptoms, and slow disease progression.
Achievements
Case Studies
Acute Lymphoblastic Leukemia (ALL)
A study in Blood highlighted the success of CAR-T cell therapy (tisagenlecleucel) in pediatric and young adult patients with relapsed/refractory ALL. Over 80% achieved complete remission within one month of treatment, with sustained responses observed in more than 50% at 12 months.
Non-Small Cell Lung Cancer (NSCLC)
Research published in Nature showed that combining nivolumab (anti-PD-1) with ipilimumab (anti-CTLA-4) significantly improved progression-free survival in advanced NSCLC patients. The combination therapy demonstrated a 36% reduction in disease progression risk compared to chemotherapy.
Melanoma
A pivotal study in The New England Journal of Medicine demonstrated the efficacy of immune checkpoint inhibitors like pembrolizumab (anti-PD-1) in advanced melanoma. Patients experienced a 5-year overall survival rate of 43%, with durable tumor regression and manageable side effects, marking a breakthrough in melanoma treatment.
Cystic Fibrosis
A trial targeting CFTR gene mutations delivered via aerosolized vectors showed improved pulmonary function in patients with cystic fibrosis. Published in The Lancet Respiratory Medicine, the therapy reduced hospitalizations and improved quality of life metrics over 12 months.
Hemophilia B
Gene therapy using an AAV vector to deliver the FIX gene resulted in sustained Factor IX production in patients. A landmark study in Blood reported a significant reduction in bleeding episodes and factor replacement therapy use, lasting up to 5 years.
Leber’s Congenital Amaurosis (LCA)
The gene therapy Luxturna restored partial vision in patients with RPE65 gene mutations. Clinical trials demonstrated improved light sensitivity and navigation abilities, with effects persisting for over three years.
